Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study

Fanouriakis A., Adamichou C., Koutsoviti S., Panopoulos S., Staveri C., Klagou A., ...More

SEMINARS IN ARTHRITIS AND RHEUMATISM, vol.48, no.3, pp.467-474, 2018 (SCI-Expanded) identifier identifier identifier


Background: Low disease activity is a validated target of current systemic lupus erythematosus (SLE) therapy. The aim of this study was to assess the ability of belimumab to achieve low disease activity states in real-life settings.